Testing offers CBR families the opportunity to
proactively seek additional information about their child's
health
TRUMBULL, Conn. and EL MONTE, Calif., Feb. 9, 2024
/PRNewswire/ -- CooperSurgical®, a global leader in
fertility and women's health, and Fulgent Genetics, Inc. (NASDAQ:
FLGT), a technology-based company with a well-established clinical
diagnostic business and a therapeutic development business, today
announced that they have partnered to offer families of Cord Blood
Registry® (CBR®) exclusive newborn genetic
screening panels.
"We are proud to offer our CBR families additional resources
that complement our newborn stem cell services as we continue to
deliver personalized, cutting-edge solutions to families
nationwide," said Holly Sheffield,
President of CooperSurgical.
Utilizing Fulgent's Picture® Genetics platform, CBR,
the largest private newborn stem cell preservation company in the
world, now offers a range of genetic testing options to its
families, including:
- CBR Snapshot™ genetic test – screens children for
over 250 genes related to metabolic disorders, blood
disorders, cancers, cardiovascular disorders, and hearing/vision
loss where early detection may provide actionable information and
may be managed with medication, diet, or other
therapies.1
- CBR Portrait™ genetic test –
screens children for over 600 genes, covering
everything in CBR Snapshot, plus additional genes related to
hearing loss, actionable epilepsy, immunodeficiency, heart
conditions, and neonatal diabetes. CBR Portrait includes more than
twice as many genes as CBR Snapshot and may identify more rare
causes of these conditions. If a patient were to test negative, the
results further reduce the likelihood that a patient has the
conditions included on the test.1
- CBR Landscape™ genetic test – screens children for over
1,500 genes, covering everything in CBR Snapshot and CBR Portrait,
plus genes associated with an even broader range of genetic
conditions. CBR Landscape also includes a pharmacogenetic
(PGx) component, which is a type of genetic testing that can
determine how a person breaks down or metabolizes certain
medications. This test can identify a potential for adverse
reactions to more than 100 medications.1 It is one of
the most comprehensive pediatric genetic tests
available.1
"Partnering with CBR allows us to help provide more families
with actionable information about their newborn's health," said
Brandon Perthuis, Chief Commercial
Officer of Fulgent Genetics. "Part of our mission is to use our
resources and testing to improve the lives of those around us.
Newborn genetic analysis serves as an illustration of this
commitment, as early intervention may significantly improve health
outcomes for many of these conditions."
These Picture Genetic tests are available now exclusively to CBR
clients. All three Picture tests evaluate over 30 genes associated
with conditions that are potentially treatable with newborn stem
cells as part of a stem cell transplant.1
For more information, please visit
www.cordblood.com/genetic-testing.
About CBR® by
CooperSurgical
Cord Blood Registry (CBR) is the largest private newborn stem
cell company in the world, helping parents store stem cells from
cord blood and cord tissue for their children. Founded in 1994, CBR
is the #1 choice for parents1 and most recommended by
OB/GYNs for newborn stem cell preservation.2 The company
has released over 700 samples intended for use in transplant
medicine and regulated investigational regenerative medicine
applications.1 CBR is here to help expand the
possibilities of what newborn stem cell therapies can do for
families and give parents the confidence to Bank on CBR™. More
information can be found at www.cordblood.com.
About CooperSurgical®
CooperSurgical is a leading fertility and women's healthcare
company dedicated to putting time on the side of women, babies, and
families at the healthcare moments that matter most in life.
CooperSurgical is at the forefront of delivering innovative
assisted reproductive technology and genomic solutions that enhance
the work of ART professionals to the benefit of families. We
currently offer over 600 clinically relevant medical devices to
women's healthcare providers, including testing and treatment
options.
CooperSurgical is a wholly-owned subsidiary of CooperCompanies
(Nasdaq: COO). CooperSurgical, headquartered in Trumbull,
CT, produces and markets a wide array of products and services for
use by women's health care clinicians. More information can be
found at www.coopersurgical.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device
company focused on improving lives one person at a time. The
Company operates through two business units, CooperVision and
CooperSurgical. CooperVision is a trusted leader in the contact
lens industry, improving the vision of millions of people every
day. CooperSurgical is a leading fertility and women's health
company dedicated to assisting women, babies, and families at the
healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies ("Cooper") has
a workforce of more than 15,000 with products sold in over 130
countries. For more information, please
visit www.coopercos.com.
About Picture® Genetics
Picture Genetics was launched in 2019 as a service of Fulgent
Genetics. Picture Genetics offers consumers direct access to
Fulgent's advanced genetic testing and analytics capabilities from
the ease and comfort of home, at an affordable price point. With
multiple tests available to meet the varying needs of consumers,
Picture Genetics provides a holistic approach to at-home genetic
screening to complement Fulgent's comprehensive genetic testing
analysis. Picture Genetics reports provide medically actionable,
clinical-level results with professional medical oversight in one
easy process. Visit www.picturegenetics.com for more
information.
About Fulgent
Fulgent is a technology-based company with a well-established
clinical diagnostic business and a therapeutic development
business. Fulgent's clinical diagnostic business offers molecular
diagnostic testing services, comprehensive genetic testing, and
high-quality anatomic pathology laboratory services designed to
provide physicians and patients with clinically actionable
diagnostic information to improve the quality of patient care.
Fulgent's therapeutic development business is focused on developing
drug candidates for treating a broad range of cancers using a novel
nanoencapsulation and targeted therapy platform designed to improve
the therapeutic window and pharmacokinetic profile of new and
existing cancer drugs. The company aims to transform from a genomic
diagnostic business into a fully integrated precision medicine
company.
References
- Internal data on file.
- Blind survey, Egg Strategy, 10/19, funded by CBR.
Contact
CooperSurgical
EvolveMKD
csi@evolvemkd.com
Fulgent Genetics
Melanie Soloman, The Blueshirt
Group
melanie@blueshirtgroup.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cord-blood-registry-cbr-by-coopersurgical-and-fulgent-genetics-launch-innovative-genetic-testing-302058232.html
SOURCE CooperSurgical®